| NOVARTIS AG-REG | 80,28 / -0,02% |
| Data / Laikas | 28.06. / 18:20 |
| Pok. / Pok.(%) | -0,02 / -0,02% |
| Bid | 79,84 / 625 |
| Ask | 80,74 / 625 |
| Atidaryti | 80,22 |
| Ankstesnį uždaryti | 80,30 |
| Aukšč. | 80,28 |
| Žem. | 80,18 |
| APYVARTA [EUR] | 10.029,74 |
| APYVARTA [Units] | 125 |
| Price fixings | 3 |
| ISIN | CH0012005267 |
| Simbolis | NOT/D |
| Birža | Turquoise |
| Rūšis | Stock |
Visos biržos
| Birža | Paskutinis | APYVARTA | |
|---|---|---|---|
| SIX Swiss Ex.. | 91,85 |  |
506.790 |
| London Inter.. | 91,85 | |
845 |
| Lang & Schwa.. | 83,360 | |
|
| Nasdaq Other.. | 94,0075 | |
41.167 |
| Cboe Europe .. | 89,12 | 725.512 | |
| Cboe Europe .. | 89,12 | 520.892 | |
| Turquoise | 89,12 | |
146.333 |
| Xetra | 80,34 | 24.840 | |
| TradeGate | 80,000 | 16.350 | |
| Cboe Europe .. | 80,29 | 2.465 | |
| Frankfurt | 80,160 | 1.589 | |
| Cboe Europe .. | 80,25 | 1.286 | |
| Borsa Italia.. | 79,20 | 1.042 | |
| Hamburg | 80,19 | 1.000 | |
| Stuttgart | 80,100 | 513 | |
| Turquoise | 80,28 | |
125 |
| München | 80,10 | 55 | |
| Berlin | 80,40 | 40 | |
| gettex | 80,160 | 20 | |
| Düsseldorf | 80,18 | 4 | |
| Hannover | 80,10 | 0 | |
| Borsa Italia.. | 75,00 | 36 | |
| EUREX | Options | ||
Naujienos
- Genmab Announces the Closing of Over-Allotment Option in Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase
23.07.2019 / 17:28 - GlobeNewswire - Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis
22.07.2019 / 07:15 - GlobeNewswire - Novartis reports 12.5% drop in profit to $6.8B
18.07.2019 / 07:29 - TeleTrader - Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased
18.07.2019 / 07:00 - GlobeNewswire - FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
16.07.2019 / 07:15 - GlobeNewswire